Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.tips.2020.06.007 http://scihub22266oqcxt.onion/10.1016/j.tips.2020.06.007 32580895!7298494!32580895     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Trends+Pharmacol+Sci 2020 ; 41 (8): 531-543 Nephropedia Template TP {{tp|p=32580895|t=2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19 |pdf=|usr=}}{{32580895}} gab.com Text Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19 JO: Trends Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32580895 #FOAvip Recent advances in the pathophysiologic understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc. Therefore, the treatment of cytokine storm has been proposed as a critical part of rescuing severe COVID-19. Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clinical outcomes in COVID-19. Below, we review the possibilities and challenges of targeting the pathway in COVID-19. Twit Text FOAVip Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19 ????Trends Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32580895 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32580895 #FOAvip English Wikipedia <ref>{{Cite pmid|32580895}}</ref> Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19 #MMPMID32580895 Luo W; Li YX; Jiang LJ; Chen Q; Wang T; Ye DW Trends Pharmacol Sci 2020[Aug]; 41 (8): 531-543 PMID32580895show ga Recent advances in the pathophysiologic understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc. Therefore, the treatment of cytokine storm has been proposed as a critical part of rescuing severe COVID-19. Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clinical outcomes in COVID-19. Below, we review the possibilities and challenges of targeting the pathway in COVID-19. |Animals[MESH] |Betacoronavirus/*isolation & purification[MESH] |COVID-19[MESH] |Coronavirus Infections/drug therapy/immunology/*physiopathology[MESH] |Cytokine Release Syndrome/drug therapy/immunology/*virology[MESH] |Cytokines/immunology[MESH] |Humans[MESH] |Janus Kinases/metabolism[MESH] |Pandemics[MESH] |Pneumonia, Viral/drug therapy/immunology/*physiopathology[MESH] |SARS-CoV-2[MESH] |STAT Transcription Factors/metabolism[MESH]Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in C(epmc).pdf DeepDyve Pubget Overpricing